Markets - BioReview (Page 2)

Biotechnology

After the Vaccine: What BioNTech's Founder Exodus Reveals About the Future of mRNA

BioNTech's co-founders are stepping down to launch a new mRNA startup. What does this mean for the company's oncology pipeline and the future of mRNA technology?

Markets

Lilly's Employer Gambit: How the GLP-1 Giant Is Rewriting the Rules of Drug Distribution

Eli Lilly's new Employer Connect platform lets workers buy Zepbound at $449/month, bypassing insurers entirely. It is a bold bet that pharma companies can rewrite the rules of drug distribution before compounders and insurers do it for them.

Pharmaceuticals

Canada's Generic Ozempic Revolution Begins Today: Vimy Pharma Leads Charge as Patent Protections Expire

January 4, 2026, marks a watershed moment in the global GLP-1 market as Canada becomes the first country where Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic loses patent protection. Leading the charge into this newly opened market is Toronto-based Vimy Pharma, a startup founded by former Novo

Biotechnology

BioMarin's $4.8 Billion Amicus Acquisition Reshapes Rare Disease Landscape

BioMarin Pharmaceutical's announcement of its $4.8 billion acquisition of Amicus Therapeutics represents one of the most significant consolidation moves in the rare disease sector, signaling a new era of strategic positioning as companies seek to build comprehensive portfolios in specialized therapeutic areas. The all-cash transaction, announced December

Biotechnology

AbbVie's $1.2 Billion Zelgen Deal Signals Major Push Into T-Cell Engager Market

AbbVie kicked off 2026 with a strategic bang, announcing a potentially $1.2 billion licensing deal with China's Suzhou Zelgen Biopharmaceuticals for exclusive rights to develop and commercialize alveltamig (ZG-006) outside of Greater China. The New Year's Eve agreement represents one of the largest T-cell engager